CINECA IRIS Institutional Research Information System

BOCCI, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.827
AS - Asia 9.887
EU - Europa 7.361
SA - Sud America 1.333
AF - Africa 434
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 42.873
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.256
SG - Singapore 3.050
CN - Cina 2.704
IT - Italia 2.363
HK - Hong Kong 1.647
BR - Brasile 1.090
SE - Svezia 1.086
VN - Vietnam 897
DE - Germania 891
BG - Bulgaria 640
CA - Canada 444
TR - Turchia 444
FR - Francia 441
GB - Regno Unito 441
FI - Finlandia 369
RU - Federazione Russa 300
UA - Ucraina 259
IN - India 241
JP - Giappone 208
CI - Costa d'Avorio 161
KR - Corea 139
BD - Bangladesh 111
AT - Austria 108
CH - Svizzera 96
AR - Argentina 75
MX - Messico 65
NL - Olanda 62
IQ - Iraq 59
BE - Belgio 55
PL - Polonia 55
SA - Arabia Saudita 50
NG - Nigeria 46
ZA - Sudafrica 43
PK - Pakistan 42
GR - Grecia 40
ID - Indonesia 40
MA - Marocco 36
SN - Senegal 36
CO - Colombia 35
ES - Italia 34
EC - Ecuador 33
UZ - Uzbekistan 33
VE - Venezuela 30
KE - Kenya 22
PY - Paraguay 22
AU - Australia 21
PH - Filippine 20
EG - Egitto 18
TN - Tunisia 18
CZ - Repubblica Ceca 17
JO - Giordania 17
IE - Irlanda 16
IL - Israele 16
LT - Lituania 16
IR - Iran 15
UY - Uruguay 15
AE - Emirati Arabi Uniti 14
CL - Cile 14
MY - Malesia 14
NP - Nepal 14
PS - Palestinian Territory 14
PE - Perù 13
RO - Romania 13
TT - Trinidad e Tobago 13
BJ - Benin 11
DK - Danimarca 11
DZ - Algeria 11
OM - Oman 11
AZ - Azerbaigian 10
HU - Ungheria 9
LB - Libano 9
CR - Costa Rica 8
JM - Giamaica 8
KZ - Kazakistan 8
BB - Barbados 7
DO - Repubblica Dominicana 7
ET - Etiopia 7
HR - Croazia 7
KW - Kuwait 7
TH - Thailandia 7
AL - Albania 6
AM - Armenia 6
KH - Cambogia 6
PT - Portogallo 6
TW - Taiwan 6
BO - Bolivia 5
NO - Norvegia 5
NZ - Nuova Zelanda 5
BW - Botswana 4
GE - Georgia 4
KG - Kirghizistan 4
NI - Nicaragua 4
RS - Serbia 4
SY - Repubblica araba siriana 4
BH - Bahrain 3
GA - Gabon 3
LK - Sri Lanka 3
AG - Antigua e Barbuda 2
BN - Brunei Darussalam 2
BS - Bahamas 2
Totale 42.819
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.819
Ashburn 2.232
Ann Arbor 1.960
Houston 1.898
Fairfield 1.826
Singapore 1.741
Hong Kong 1.620
Chandler 1.176
Dallas 1.130
San Jose 1.085
Santa Clara 1.052
Seattle 862
Wilmington 713
Cambridge 687
Sofia 638
Shanghai 604
Beijing 559
Milan 551
Serra 480
New York 425
Boardman 359
Ottawa 350
Jacksonville 296
Los Angeles 293
Princeton 274
Izmir 272
Lawrence 257
Lauterbourg 233
Medford 220
Nanjing 200
Ho Chi Minh City 199
Tokyo 182
Des Moines 164
Abidjan 161
Dong Ket 159
Council Bluffs 156
Hefei 155
Hanoi 154
Dearborn 153
Munich 136
Istanbul 127
Seoul 125
London 104
Redondo Beach 103
Frankfurt am Main 102
Buffalo 94
Pisa 94
Florence 93
The Dalles 92
Nanchang 91
San Diego 90
Columbus 89
Rome 86
São Paulo 86
Vienna 86
Falls Church 83
Helsinki 82
Bern 80
Washington 80
Boulder 75
Ogden 68
Turku 68
Redwood City 58
Düsseldorf 57
Brussels 52
Jüchen 51
Bremen 50
Lagos 45
Warsaw 45
Kunming 44
Rio de Janeiro 41
Hebei 40
Shenyang 39
Changsha 37
Dakar 36
Belo Horizonte 35
Fuzhou 35
Lucca 35
Norwalk 35
Pune 35
Marseille 34
Da Nang 32
Guangzhou 32
Rho 31
Nuremberg 30
Tashkent 30
Nürnberg 29
Jiaxing 28
Phoenix 28
Seacroft 28
Tianjin 28
Haiphong 27
Orem 27
Baltimore 24
Toronto 24
Hangzhou 23
Montreal 23
Mumbai 23
Atlanta 22
Chicago 22
Totale 31.744
Salva come PNG Salva come JPEG
Nome #
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions 407
A new class of tyrosine kinase inhibitors, “pyrazolo[3,4-d]pyrimidinic”compounds, has antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer 371
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity 352
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 298
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy 284
A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma 272
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 267
John Hunter and the origin of the term “angiogenesis”. 257
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 255
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 252
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 249
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy 249
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 247
Gender, MGMT methylation, and levetiracetam plasma levels correlate with survival benefit in glioblastoma patients treated with adjuvant temozolomide: results from a non-interventional retrospective clinical study 246
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 243
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 242
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study 240
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients 239
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 235
Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia 233
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. 228
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 226
Angiogenesis and VEGF expression in pre-invasive lesions of the human breast. 215
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients 213
Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: how to escape and move forward? 212
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 209
Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo 209
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2 209
5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer 208
The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. 206
Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. 205
Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity 204
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. 201
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. 200
An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients 198
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies 197
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 196
Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation 195
5-Fluorouracil exposure in adjuvant chemotherapy regimens is significantly related to disease free survival in colorectal cancer patients 194
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 194
Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy 194
Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro 193
Chronic administration of suramin induces neurotoxicity in rats 192
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 192
Methods: For studying pharmacogenetic profiles of combination chemotherapeutic drugs 191
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine 188
Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents 187
The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization 187
Appropriateness of repetitive therapeutic drug monitoring and laboratory turn around time 187
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 186
Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation 185
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 184
Three-dimensional in vitro culture of endometrial explants mimics the early stages of endometriosis 183
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. 183
Tumor Dormancy, Angiogenesis and Metronomic Chemotherapy 183
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy 182
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 182
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World 182
Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice 181
Scholars and scientists in the history of the lymphatic system 181
Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib 180
The pharmacological bases of the antiangiogenic activity of paclitaxel 180
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 179
New antiproliferative agents derived from tricyclic 3,4-dihydrobenzo[4,5]imidazo[1,2-a][1,3,5]triazine scaffold: synthesis and pharmacological effects 178
Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate 178
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 177
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 177
Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): a phase II clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination 176
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. 174
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer 173
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 172
Old and New Systemic Immune-Inflammation Indexes Are Associated with Overall Survival of Glioblastoma Patients Treated with Radio-Chemotherapy 171
Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules 171
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells 171
Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. 171
ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. 169
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 168
Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter 168
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. 166
Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib ( C ) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamic results 165
Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell lines 165
Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation 164
In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists 164
Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going? 163
5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer 163
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 163
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients 162
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 162
Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling 162
Pharmacogenetics of Antiangiogenic Therapy 161
Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients 161
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib 161
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer 160
Metronomic chemotherapy (MC) with oral Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 159
Endometriosis Index: A software-derived score to predict the presence and severity of the disease 159
5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice 159
Derivati a nucleo benzo[d]isotiazol-3(2H)-one-1,1-diossido e loro impiego nel trattamento di tumori 159
Looking for the Word “Angiogenesis” in the History of Health Sciences: From Ancient Times to the First Decades of the Twentieth Century 157
Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 156
The Biomodulatory Capacities of Low-Dose Metronomic Chemotherapy: Complex Modulation of the Tumor Microenvironment 156
Totale 19.960
Salva come PNG Salva come JPEG
Categoria #
all - tutte 117.007
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 117.007
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021501 0 0 0 0 0 0 0 0 0 0 125 376
2021/20222.884 50 209 79 132 494 489 91 128 128 115 158 811
2022/20233.577 463 445 254 331 447 458 13 269 636 21 196 44
2023/20242.569 302 289 318 171 350 466 77 108 65 47 104 272
2024/20258.284 45 335 80 452 746 864 649 448 860 1.119 863 1.823
2025/20269.454 659 1.208 1.253 834 986 841 1.487 521 674 918 73 0
Totale 43.506